2 results
Approved WMOCompleted
Part 1: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to…
Approved WMOPending
- to reduce the prevalence of Heart Failure (HF) in cancer survivors- to improve screening strategies for early diagnosis of anthracycline-induced cardiotoxicity (AIC)Also the following objectives:- to identify early cardiotoxicity markers- to…